AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21746944 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole 200 mg QD for 24 weeks
Number of subjects: 146
Study 21746944 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole 400 mg QD for 24 weeks
Number of subjects: 146
Study 21746944 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole 400 mg QD for 12 weeks
Number of subjects: 146
Study 18728054 — intervention group
Group type: EXPERIMENTAL
Intervention: Six‐month supervised aerobic and strength training
Number of subjects: 115
Study 17719940 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillectomy
Number of subjects: 26
Study 17719940 — intervention group
Group type: COMPARATOR
Intervention: Control (follow-up alone)
Number of subjects: 26
Study 15243282 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT)
Number of subjects: 136
Study 15243282 — intervention group
Group type: COMPARATOR
Intervention: Non-hormone therapy (non-HT)
Number of subjects: 136
Study 11044778 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical FC severity scale
Number of subjects: 40
Study 11044778 — intervention group
Group type: EXPERIMENTAL
Intervention: Variability in attentional performance
Number of subjects: 40
Study 11044778 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow EEG rhythms across 90 s, 1 h and 1 week
Number of subjects: 40
Study 11044778 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical ratings of FC
Number of subjects: 40
Study 9388905 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose vaccine (5 mg rBS and 10^8 WC)
Number of subjects: 369
Study 9388905 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose vaccine (1 mg rBS and 10^8 WC)
Number of subjects: 369
Study 9388905 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 369
Study 1414052 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG solution (Oralav)
Number of subjects: 110
Study 1414052 — intervention group
Group type: COMPARATOR
Intervention: Ringer's lactate solution (control group)
Number of subjects: 110
Study 1414052 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 110
Study 2578107 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (150 micrograms/kg intravenous bolus followed by 150 micrograms/kg/hr intravenous infusion)
Number of subjects: 35
Study 2578107 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 35
Study 31561278 — intervention group
Group type: EXPERIMENTAL
Intervention: sirolimus
Number of subjects: 238
Study 31561278 — intervention group
Group type: COMPARATOR
Intervention: MMF
Number of subjects: 238
Study 31649376 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily mud packs and bicarbonate-alkaline mineral water baths
Number of subjects: 66
Study 31649376 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal hydrotherapy rehabilitation scheme
Number of subjects: 66
Study 31649376 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of mud packs and thermal hydrotherapy
Number of subjects: 66
Study 31649376 — intervention group
Group type: COMPARATOR
Intervention: Usual medication only
Number of subjects: 66
Study 30155979 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocrelizumab (600 mg)
Number of subjects: 699
Study 30155979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 699
Study 27325147 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-based treatment (n=92; 46 adrenalectomy, 46 mineralocorticoid receptor antagonist)
Number of subjects: 200
Study 27325147 — intervention group
Group type: EXPERIMENTAL
Intervention: AVS-based treatment (n=92; 46 adrenalectomy, 46 mineralocorticoid receptor antagonist)
Number of subjects: 200
Study 27325147 — intervention group
Group type: COMPARATOR
Intervention: CT-based adrenalectomy
Number of subjects: 200
Study 27325147 — intervention group
Group type: EXPERIMENTAL
Intervention: AVS-based adrenalectomy
Number of subjects: 200
Study 27325147 — intervention group
Group type: COMPARATOR
Intervention: CT-based treatment
Number of subjects: 200
Study 27325147 — intervention group
Group type: EXPERIMENTAL
Intervention: AVS-based treatment
Number of subjects: 200
Study 27325147 — intervention group
Group type: COMPARATOR
Intervention: AVS compared to CT
Number of subjects: 200
Study 24957302 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training
Number of subjects: 175
Study 24957302 — intervention group
Group type: COMPARATOR
Intervention: Matched control (American Lung Association's Freedom From Smoking program)
Number of subjects: 175
Study 22056854 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin 60 mg/m2 + Cyclophosphamide 600 mg/m2 every 21 days for four cycles
Number of subjects: 181
Study 22056854 — intervention group
Group type: COMPARATOR
Intervention: Pegylated liposomal doxorubicin 35 mg/m2 + Cyclophosphamide + Trastuzumab 2 mg/kg weekly for 12 weeks
Number of subjects: 181
Study 22056854 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Number of subjects: 181
Study 22056854 — intervention group
Group type: COMPARATOR
Intervention: Pegylated liposomal doxorubicin
Number of subjects: 181
Study 19041197 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT4CBT (computer-based training for CBT)
Number of subjects: 73
Study 19041197 — intervention group
Group type: COMPARATOR
Intervention: TAU (treatment-as-usual)
Number of subjects: 73
Study 17258146 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg/day)
Number of subjects: 30
Study 17258146 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg/day) + resistance exercise
Number of subjects: 30
Study 17258146 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 15059509 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane induced hypotension (group A)
Number of subjects: 30
Study 15059509 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane maintained anesthesia (group B)
Number of subjects: 30
Study 12042982 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (70 mg/m²) plus Ifosfamide (5 g/m²) followed by radiotherapy (chemotherapy arm)
Number of subjects: 370
Study 12042982 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide (250 mg/m²) + Ifosfamide (6 g/m²) + Doxorubicin (50 mg/m²) within 12 weeks (chemotherapy arm)
Number of subjects: 370
Study 12042982 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide (250 mg/m²) + Ifosfamide (6 g/m²) + Doxorubicin (50 mg/m²) combined with regional hyperthermia (RHT + chemotherapy arm)
Number of subjects: 370
Study 12042982 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone with no further treatment (observation arm)
Number of subjects: 370
Study 9667341 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 60
Study 9667341 — intervention group
Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 60
Study 7814832 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral GHBA administration
Number of subjects: 9
Study 7814832 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral GHBA and i.v. flumazenil administration
Number of subjects: 9
Study 7814832 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo and i.v. saline administration
Number of subjects: 9
Study 2761740 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide alone or in addition to conventional therapies
Number of subjects: 140
Study 2761740 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide with conventional therapies
Number of subjects: 140
Study 772696 — intervention group
Group type: EXPERIMENTAL
Intervention: pemoline
Number of subjects: 30
Study 772696 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 29701814 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 IU)
Number of subjects: 35
Study 29701814 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 35
Study 28145801 — intervention group
Group type: EXPERIMENTAL
Intervention: 2′MOE ASOs
Number of subjects: 2638
Study 25739031 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinyl-estradiol 0.03 mg + Drospirenone 3 mg (EE + DRSP)
Number of subjects: 106
Study 25739031 — intervention group
Group type: COMPARATOR
Intervention: Ethinyl-estradiol 0.03 mg + Chlormadinone acetate 2 mg (EE + CMA)
Number of subjects: 106
Study 23609610 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐HTP (three 50‐mg capsules)
Number of subjects: 68
Study 23609610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 21270376 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie information
Number of subjects: 178
Study 21270376 — intervention group
Group type: EXPERIMENTAL
Intervention: Tax of ≥25% on high-calorie foods
Number of subjects: 178
Study 21270376 — intervention group
Group type: EXPERIMENTAL
Intervention: Price increase for high-calorie foods (125% and 150% of base price)
Number of subjects: 178
Study 21270376 — intervention group
Group type: COMPARATOR
Intervention: No calorie information
Number of subjects: 178
Study 19952467 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (aspirin 100 mg, clopidogrel 75 mg, and triflusal 300 mg per day)
Number of subjects: 190
Study 19952467 — intervention group
Group type: COMPARATOR
Intervention: Dual therapy (aspirin 100 mg and clopidogrel 75 mg per day)
Number of subjects: 190
Study 17457600 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D ultrasound
Number of subjects: 60
Study 17457600 — intervention group
Group type: COMPARATOR
Intervention: 2D ultrasound
Number of subjects: 60
Study 15473126 — intervention group
Group type: COMPARATOR
Intervention: Diet + Orlistat (group 1; n = 30 patients)
Number of subjects: 89
Study 15473126 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + Sibutramine (group 2; n = 29 patients)
Number of subjects: 89
Study 15473126 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + Orlistat + Sibutramine (group 3; n = 30 patients)
Number of subjects: 89
Study 10676676 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic treatment (300 mg three times a day for three months)
Number of subjects: 50
Study 10676676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 10676676 — intervention group
Group type: COMPARATOR
Intervention: Garlic treatment or Placebo in LDL pattern A subjects
Number of subjects: 50
Study 9377680 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy to maximal dose 6000 cGy (group I)
Number of subjects: 54
Study 9377680 — intervention group
Group type: COMPARATOR
Intervention: Short radiotherapy (4 x 500 cGy) (group II)
Number of subjects: 54
Study 8462377 — intervention group
Group type: EXPERIMENTAL
Intervention: benfluorex
Number of subjects: 10
Study 8462377 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 3080173 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen at 2 atmospheres absolute
Number of subjects: 84
Study 3080173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 31631033 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted PA message
Number of subjects: 60
Study 31631033 — intervention group
Group type: COMPARATOR
Intervention: Non-inclusive PA message
Number of subjects: 60
Study 31631033 — intervention group
Group type: COMPARATOR
Intervention: No youth PA message
Number of subjects: 60
Study 30514278 — intervention group
Group type: EXPERIMENTAL
Intervention: Flipped Classroom (FC) e-learning program
Number of subjects: 212
Study 30514278 — intervention group
Group type: COMPARATOR
Intervention: Control group (no access to e-learning program)
Number of subjects: 212
Study 26900092 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT) with 66 Gy in 24 fractions and daily low dose cisplatin
Number of subjects: 226
Study 26900092 — intervention group
Group type: EXPERIMENTAL
Intervention: Log10(Volume) of primary tumor and lymph nodes
Number of subjects: 226
Study 25710563 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 24
Study 25710563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 23088285 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly defined clinical pathway
Number of subjects: 50
Study 21915516 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.23% acidulated phosphate fluoride gel, pH 4.1
Number of subjects: 36
Study 21915516 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% potassium oxalate gel, pH 4.1 (Oxa-Gel®)
Number of subjects: 36
Study 21915516 — intervention group
Group type: EXPERIMENTAL
Intervention: iron sulfate gel (10 mmol/L FeSO4), pH 4.1
Number of subjects: 36
Study 21915516 — intervention group
Group type: COMPARATOR
Intervention: Presence of smear layer
Number of subjects: 36
Study 19033181 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive recommended treatment and lifestyle advice in cardiovascular prevention (observational design)
Number of subjects: 12500
Study 19033181 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 polyunsaturated fatty acid (randomized controlled trial design)
Number of subjects: 12500
Study 16556241 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Migraine (CM)
Number of subjects: 71
Study 16556241 — intervention group
Group type: EXPERIMENTAL
Intervention: Probable Chronic Migraine (PCM) and Probable Analgesic-Abuse Headache (PAAH)
Number of subjects: 71
Study 16556241 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Fibromyalgia Syndrome (PFMS)
Number of subjects: 71
Study 16556241 — intervention group
Group type: COMPARATOR
Intervention: Control Subjects
Number of subjects: 71
Study 16556241 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between CSF values of GDNF and somatostatin in CM
Number of subjects: 71
Study 16556241 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between CSF values of GDNF and somatostatin in PCM + PAAH
Number of subjects: 71
Study 16556241 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between CSF values of GDNF and somatostatin in PFMS
Number of subjects: 71
Study 14636820 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress manipulation (speech task)
Number of subjects: 100
Study 14636820 — intervention group
Group type: COMPARATOR
Intervention: Nonstress control condition (magazine reading)
Number of subjects: 100
Study 10068846 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 167
Study 10068846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study 8523015 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative and postoperative Cell‐Saver (Haemonetics, Braintree, MA)
Number of subjects: 153
Study 8523015 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative Solcotrans (Smith & Nephew Richards, Memphis, TN) reinfusion protocol
Number of subjects: 153
Study 8523015 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed‐suction Hemovac drain (Zimmer, Warsaw, IN)
Number of subjects: 153
Study 8523015 — intervention group
Group type: EXPERIMENTAL
Intervention: No drain used
Number of subjects: 153
Study 1741708 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc gluconate
Number of subjects: 98
Study 1741708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 6111672 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin administration
Number of subjects: 23
Study 6111672 — intervention group
Group type: COMPARATOR
Intervention: Control (no prostacyclin)
Number of subjects: 23
Study 31036397 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus eluting stents (EES)
Number of subjects: 1821
Study 31036397 — intervention group
Group type: COMPARATOR
Intervention: Thin-strut paclitaxel eluting stents (PES)
Number of subjects: 1821
Study 31036397 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent related events (TV-MI, TVR, TLR and stent thrombosis)
Number of subjects: 1821
Study 28651589 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural Activation (BA) delivered by trained mental health nurses, consisting of 8 weekly 30-minute sessions.
Number of subjects: 0
Study 28651589 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) in primary care.
Number of subjects: 0
Study 25455796 — intervention group
Group type: EXPERIMENTAL
Intervention: Website with tailored information and question prompt (QP)
Number of subjects: 197
Study 25455796 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 197
Study 23934877 — intervention group
Group type: EXPERIMENTAL
Intervention: Group hearing aid fitting visits
Number of subjects: 644
Study 23934877 — intervention group
Group type: EXPERIMENTAL
Intervention: Group hearing aid follow-up visits
Number of subjects: 644
Study 23934877 — intervention group
Group type: COMPARATOR
Intervention: Individual hearing aid fitting visits
Number of subjects: 644
Study 23934877 — intervention group
Group type: COMPARATOR
Intervention: Individual hearing aid follow-up visits
Number of subjects: 644
Study 21646576 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus group cognitive behavioral therapy (16 sessions of 2 hours each)
Number of subjects: 299
Study 21646576 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 299
Study 19654947 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubular retractor assisted foraminotomy/discectomy (TAF/TAFD)
Number of subjects: 41
Study 19654947 — intervention group
Group type: COMPARATOR
Intervention: Open foraminotomy/discectomy (OF/OFD)
Number of subjects: 41
Study 16995862 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclometasone
Number of subjects: 30
Study 16995862 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 30
Study 16995862 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone
Number of subjects: 30
Study 16995862 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone
Number of subjects: 30
Study 15528912 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste fluoridation (SnF2/Olaflur; 0.14% F‐) for 3 x 5 min daily
Number of subjects: 10
Study 15528912 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive fluoridation (Toothpaste + Mouthrinse (SnF2/Olaflur; 0.025% F‐) for 3 x 5 min daily + Gel (NaF/Olaflur, 1.25% F‐) on days 1 and 3)
Number of subjects: 10
Study 15528912 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fluoridation)
Number of subjects: 10
Study 12019102 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5% acyclovir-1% hydrocortisone cream (ME-609)
Number of subjects: 380
Study 12019102 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control (placebo)
Number of subjects: 380
Study 9715184 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial liquid ventilation (PLV)
Number of subjects: 16
Study 9715184 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (CMV)
Number of subjects: 16
Study 7494183 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium controlled-release matrix tablets (various formulations)
Number of subjects: 6
Study 7494183 — intervention group
Group type: EXPERIMENTAL
Intervention: High viscosity grade HPMC
Number of subjects: 6
Study 7494183 — intervention group
Group type: EXPERIMENTAL
Intervention: Stability testing of diclofenac sodium formulations
Number of subjects: 6
Study 7494183 — intervention group
Group type: EXPERIMENTAL
Intervention: In-vivo study of sustained release formulations
Number of subjects: 6
Study 7494183 — intervention group
Group type: EXPERIMENTAL
Intervention: In-vitro/in-vivo correlations
Number of subjects: 6
Study 2483977 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural BCG according to McKneally's technique (73 patients)
Number of subjects: 344
Study 2483977 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (43 patients)
Number of subjects: 344
Study 2483977 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprinosine (60 patients)
Number of subjects: 344
Study 329860 — intervention group
Group type: EXPERIMENTAL
Intervention: Debendox with 10mg of extra pyridoxine
Number of subjects: 56
Study 329860 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 10mg of pyridoxine
Number of subjects: 56
Study 6817772 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) ointment
Number of subjects: 7
Study 6817772 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 7
Study 31157964 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 1125
Study 31157964 — intervention group
Group type: COMPARATOR
Intervention: Standard care (nonsteroidal antiandrogen therapy)
Number of subjects: 1125
Study 28201730 — intervention group
Group type: EXPERIMENTAL
Intervention: PRISM system
Number of subjects: 300
Study 28201730 — intervention group
Group type: COMPARATOR
Intervention: Binder condition (control)
Number of subjects: 300
Study 26628415 — intervention group
Group type: COMPARATOR
Intervention: Prolonged sitting (7.5 h)
Number of subjects: 22
Study 26628415 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing (5 min every 30 min)
Number of subjects: 22
Study 25296687 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives for breastfeeding
Number of subjects: 53
Study 22392179 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (10 mg for 2‐ to 11‐month‐olds and 20 mg for older children)
Number of subjects: 610
Study 22392179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 610
Study 20729009 — intervention group
Group type: EXPERIMENTAL
Intervention: Left anodal/right cathodal tDCS of DLPFC (n=8)
Number of subjects: 25
Study 20729009 — intervention group
Group type: EXPERIMENTAL
Intervention: Right anodal/left cathodal tDCS of DLPFC (n=9)
Number of subjects: 25
Study 20729009 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (n=8)
Number of subjects: 25
Study 20729009 — intervention group
Group type: EXPERIMENTAL
Intervention: Right anodal/left cathodal tDCS of DLPFC
Number of subjects: 25
Study 17672261 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide cement (Dycal)
Number of subjects: 67
Study 17672261 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetone‐based total‐etch adhesive (Prime&Bond NT)
Number of subjects: 67
Study 17672261 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐rinse conditioner (NRC) and Prime&Bond NT
Number of subjects: 67
Study 17672261 — intervention group
Group type: EXPERIMENTAL
Intervention: Total‐etching with 36% phosphoric acid followed by Prime&Bond NT
Number of subjects: 67